Physician profile
Maria F Theodoulou
NPI 1720174055
$1,124,933.83
in general payments reported to CMS, 2019-2025
12 companies · $197K in 2025
The $197K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147K · 2020: $93K · 2021: $63K · 2022: $174K · 2023: $246K · 2024: $206K · 2025: $197K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $487K · Travel and Lodging: $97K · Consulting Fee: $59K · Food and Beverage: $4,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $487,113.75 |
| Travel and Lodging | $97,237.61 |
| Consulting Fee | $58,627.50 |
| Food and Beverage | $4,932.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $307,050.60 | 2020-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals Lp | $248,571.07 | 2020-2025 | Enhertu, Datroway, Truqap |
| Genentech USA, INC. | $165,235.17 | 2019-2023 | Perjeta, Phesgo |
| Puma Biotechnology, INC. | $163,607.01 | 2019-2024 | Nerlynx |
| Seagen INC. | $130,717.22 | 2020-2023 | Tukysa |
| Gilead Sciences, INC. | $42,849.48 | 2021-2025 | Trodelvy |
| Pfizer INC. | $28,528.55 | 2019-2025 | |
| Stemline Therapeutics INC. | $25,159.59 | 2023-2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $9,560.22 | 2019-2025 | |
| Coherus Oncology, INC. | $2,015.48 | 2022-2024 | |
| Ge Healthcare | $889.44 | 2019 | |
| Genentech, INC. | $750.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Theodoulou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.